MDACC Study No:2006-0686 ( NCT No: NCT00414310)
Title:Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) with or without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia
Principal Investigator:Hagop Kantarjian
Treatment Agent:Decitabine; Valproic Acid
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out if decitabine, given
with or without valproic acid, can help to control AML or MDS. The safety of
both treatments will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Decitabine
Valproic Acid
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Approximately every 4-6 weeks.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults